SEATTLE, November 02, 2023 ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced the addition of multiple industry veterans to its leadership team to support its growth.
/PRNewswire/ Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of.